1- (3,5- bis(trifluoromethyl)phenyl)- 3- (4- bromo- 2- (1H- tetrazol- 5- yl)phenyl)thiourea

activates calcium-activated big-conductance potassium channels; structure in first source

Also Known As:

NS 11021; NS-11021; NS11021

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)thiourea: 7
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Thiourea: 362
      - 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)thiourea: 7
- Sulfur Compounds: 278
  - Thiourea: 362
    - 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)thiourea: 7

Experts

1.	Bentzen, Bo Hjorth: 2 articles (03/2010 - 03/2009)
2.	Grunnet, Morten: 2 articles (03/2010 - 03/2009)
3.	Olesen, Søren-Peter: 2 articles (03/2010 - 03/2009)
4.	Barbieri, Raffaella: 1 article (12/2021)
5.	Ferrera, Loretta: 1 article (12/2021)
6.	Gavazzo, Paola: 1 article (12/2021)
7.	Morabito, Rossana: 1 article (12/2021)
8.	Picco, Cristiana: 1 article (12/2021)
9.	Pusch, Michael: 1 article (12/2021)
10.	Remigante, Alessia: 1 article (12/2021)

Related Diseases

1.	Reperfusion Injury 03/01/2010 - "This suggests that NS11021 exerts its primary effect through KCa1.1 channels, which indicates an important role of these channels in protection against ischemia-reperfusion injuries. "
2.	Mucolipidoses (Sialidosis) 09/27/2016 - "In this study, we assessed the effect of BK agonist, NS1619 and NS11021 in a number of LSDs including NPC1, mild cases of mucolipidosis type IV (ML4) (TRPML1-F408∆), Niemann-Pick type A (NPA) and Fabry disease. "
3.	Fabry Disease (Fabry's Disease) 09/27/2016 - "In this study, we assessed the effect of BK agonist, NS1619 and NS11021 in a number of LSDs including NPC1, mild cases of mucolipidosis type IV (ML4) (TRPML1-F408∆), Niemann-Pick type A (NPA) and Fabry disease. "
4.	Infarction (Infarctions) 01/01/2018 - "CM NO-GC function is essential for the beneficial effects on infarct size elicited by iPost and pharmacological elevation of cGMP; however, lack of CM NO-GC does not seem to disrupt the cardioprotection mediated by the BK opener NS11021." 03/01/2010 - "In isolated perfused rat hearts subjected to ischemia-reperfusion, infarct size was reduced from 29% in control to 7% in NS11021 treated hearts. " 03/01/2009 - "3 microM NS11021 applied prior to ischemia or at the onset of reperfusion significantly reduced the infarct size [control: 44.6 +/- 2.0%; NS11021: 11.4 +/- 2.0%; NS11021 at reperfusion: 19.8 +/- 3.3% (p < 0.001 for both treatments compared to control)] and promoted recovery of myocardial performance. " 03/01/2010 - "In comparison, the inactive derivate of NS11021, i.e., NS13558, did not confer any cardioprotection, demonstrated by an infarct size identical to control hearts. "
5.	Ischemia 03/01/2010 - "In isolated perfused rat hearts subjected to ischemia-reperfusion, infarct size was reduced from 29% in control to 7% in NS11021 treated hearts. " 03/01/2009 - "3 microM NS11021 applied prior to ischemia or at the onset of reperfusion significantly reduced the infarct size [control: 44.6 +/- 2.0%; NS11021: 11.4 +/- 2.0%; NS11021 at reperfusion: 19.8 +/- 3.3% (p < 0.001 for both treatments compared to control)] and promoted recovery of myocardial performance. "

Related Drugs and Biologics

1.	NS 1619
2.	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)
3.	Glutamic Acid (Glutamate)
4.	Nifedipine (Adalat)
5.	NS13558
6.	3- ((5- chloro- 2- hydroxyphenyl)methyl)- 5- (4- (trifluoromethyl)phenyl)- 1,3,4- oxadiazol- 2(3H)- one